GlassScriptPhysician profile
Danielle M Kahn
NPI 1811683758
$7,594.35
in general payments reported to CMS, 2019-2025
46 companies · $3,230 in 2025
The $3,230 reported for 2025 was more than what 97% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $979 · 2024: $3,385 · 2025: $3,230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,495 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,495.35 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $840.13 | 2023-2025 | Piqray, Kisqali |
| E.R. Squibb & Sons, L.L.C. | $675.42 | 2023-2025 | Reblozyl, Opdivo |
| Janssen Biotech, INC. | $620.08 | 2024-2025 | Talvey, Darzalex, Rybrevant |
| Pfizer INC. | $530.42 | 2024-2025 | |
| Tempus Ai, INC | $362.39 | 2024-2025 | Xt Cdx |
| Glaxosmithkline, LLC. | $312.70 | 2024-2025 | Ojjaara, Zejula, Jemperli |
| Incyte Corporation | $303.79 | 2023-2025 | Jakafi, Jakafi |
| Takeda Pharmaceuticals U.S.A., INC. | $266.57 | 2023-2025 | Fruzaqla, Ninlaro, Iclusig |
| Astrazeneca Pharmaceuticals LP | $248.10 | 2024-2025 | Enhertu, Tagrisso |
| Adaptive Biotechnologies Corporation | $238.22 | 2023-2025 | Clonoseq |
| Janssen Pharmaceuticals, INC | $223.72 | 2023-2024 | Xarelto |
| Eisai INC. | $198.54 | 2023-2025 | |
| Abbvie INC. | $190.64 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $180.81 | 2023-2025 | Keytruda, Lynparza |
| Puma Biotechnology, INC. | $176.68 | 2024-2025 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $176.24 | 2023-2025 | Phesgo, Polivy, Alecensa |
| Stemline Therapeutics INC. | $150.67 | 2024-2025 | Orserdu |
| Daiichi Sankyo INC. | $143.91 | 2023-2025 | Enhertu, Datroway |
| Astellas Pharma US INC | $142.83 | 2024-2025 | Padcev, Xospata |
| Bayer Healthcare Pharmaceuticals INC. | $142.74 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $127.24 | 2025 | Libtayo |
| Lilly USA, LLC | $124.63 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Seagen INC. | $118.47 | 2023-2024 | Tukysa |
| Array Biopharma INC | $116.26 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Gilead Sciences, INC. | $116.18 | 2025 | Trodelvy |
| Ipsen Biopharmaceuticals, INC | $98.10 | 2024 | Onivyde, Somatuline Depot |
| Novocure INC. | $91.92 | 2024-2025 | Optune Lua (Novottf-200t), Optune Gio |
| Adc Therapeutics America, INC. | $73.91 | 2024-2025 | |
| Taiho Oncology, INC. | $62.77 | 2023-2025 | |
| Recordati_rare_diseases_inc. | $57.49 | 2024 | Sylvant |
| Legend Biotech USA INC. | $52.80 | 2024 | |
| Genzyme Corporation | $51.36 | 2023-2025 | |
| Deciphera Pharmaceuticals INC. | $50.03 | 2024 | Qinlock, Tgct |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.29 | 2025 | |
| Sobi, INC | $33.43 | 2025 | |
| Alexion Pharmaceuticals, INC. | $31.36 | 2025 | Ultomiris |
| Tersera Therapeutics LLC | $29.34 | 2024 | Zoladex |
| Csl Behring | $28.13 | 2025 | Hemgenix |
| Celgene Corporation | $25.12 | 2025 | Reblozyl |
| Tolmar, INC. | $24.02 | 2023 | |
| Servier Pharmaceuticals LLC | $23.37 | 2023 | |
| Amgen INC. | $20.91 | 2025 | Blincyto, Kyprolis |
| Geron Corporation | $19.14 | 2025 | Rytelo |
| Jazz Pharmaceuticals INC. | $17.69 | 2024 | |
| Intuitive Surgical, INC. | $14.34 | 2023 | Da Vinci Surgical System |
| Myriad Genetic Laboratories, INC. | $13.45 | 2024 | Myrisk |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Kahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.